Abstract: The present invention relates to substances and compositions thereof useful in the control of cancer stem cell persistence and concomitant tumor recurrence and/or control of tumor growth. In particular, the invention relates to substances and compositions useful in the treatment of cancers and/or tumors linked to cancer stem cells, preferably brain cancers and/or tumors, in a subject.

Abstract: A device for electrical stimulation of neural and/or muscular tissue. The device includes a cochlear implant being equipped with a power source, a speech processor, a microphone adapted to deliver sound signals to said speech processor, a current stimulator, at least an array of electrodes attached to the stimulator, and at least a signal sensor other than the microphone. The device further includes a signal transformation unit, said signal sensors being adapted to capture relevant input information and to deliver a corresponding input signal to the transformation unit, the latter allowing to transform said input signal received from the signal sensors into a modulated electrical output signal adapted to be treated by the speech processor of the cochlear implant.

Abstract: A measurement device and method for the detection of airborne particles. The device includes a nozzle designed to produce a laminar flow of air with a flow path beyond the nozzle, a first laser and a second laser being positioned for emitting time-amplitude modulated laser light with intersecting laser beams with a laser beam intersection region in a region of the air flow path, and two photodetectors positioned for the detection of laser light scattered in the laser beam intersection region by airborne particles contained in the laminar air flow. The lasers are designed for emission of time-amplitude modulated laser light of identical laser emission wavelength, and the photodetectors are positioned and designed each for the detection of scattered laser light from both lasers.

Abstract: The present invention relates to inhibitors of the oncogenic protein kinase ALK of formula (I) as herein described and pharmaceutical compositions thereof, as well as to key intermediates towards their synthesis. The compounds of formula (I) are useful in the preparation of a medicament, in particular for the treatment of cancer.

Abstract: The present invention is directed to the use of macrocyclic lactones, in particular avermectins, in the treatment of conditions whose formation, occurrence, development or growth is associated with aberrant Wnt signalling, in particular the treatment of colorectal cancer.

Abstract: The invention relates to methods of inducing insulin production in non-beta-cells or converting non-beta-cells into insulin producing cells, as well as methods of preventing and/or treating diabetes and methods of predicting the susceptibility of a diabetic subject to a treatment.

Abstract: Methods for selecting transgenic cells comprising two or more drug resistance genes with a combination of cytotoxic drugs (e.g., trimetrexate (TMTX) and hydroxyurea (HU)). Such selection can be completed in vitro or in vivo. Transgenic cells and vectors comprising combinations of resistance genes are also provided. Transgenic cells of the embodiments can be used as cell based therapeutics, such as for treatment of HIV infection.

Abstract: A device for electrical stimulation of neural and/or muscular tissue. The device includes a cochlear implant being equipped with a power source, a speech processor, a microphone adapted to deliver sound signals to said speech processor, a current stimulator, at least an array of electrodes attached to the stimulator, and at least a signal sensor other than the microphone. The device further includes a signal transformation unit, said signal sensors being adapted to capture relevant input information and to deliver a corresponding input signal to the transformation unit, the latter allowing to transform said input signal received from the signal sensors into a modulated electrical output signal adapted to be treated by the speech processor of the cochlear implant.

Abstract: The present invention relates to isolated polypeptides comprising: (i) a protein transduction domain consisting of ZEBRA or a fragment thereof that retains the capacity of internalization, (ii) at least one CD4+ epitope; and (iii) at least one CD8+ epitope. It also relates to antigen presenting cells loaded with said polypeptides, and the use thereof in immunotherapy including prevention and/or treatment of cancers or infectious diseases.

Abstract: The present invention is directed to combination formulations of monoclonal antibodies with anti-inflammatory agents, related methods and uses thereof.

Abstract: The present invention relates to a short cell penetrating peptide derived from ZEBRA, optionally linked to a cargo molecule. It also relates to a complex comprising said cell penetrating peptide and a cargo molecule, as well as cells loaded with said complex and the use thereof in therapy and diagnosis.

Abstract: The present invention is directed to a derivative selected from oxytocin, an oxytocin derivative, and an oxytocin agonist useful for the treatment of a disorder selected from obesity and insulin resistance and related methods and pharmaceutical formulations. In particular, the invention relates to a derivative selected from oxytocin, an oxytocin derivative, and an oxytocin agonist useful in the treatment of metabolic syndrome.

Abstract: Recombinant nucleic acid molecules are provided that form hair pin structures and can be used to down-regulate gene expression. For example, a nucleic acid molecule can comprise a flanking and lower stem loop sequence from a mir-16 gene; an antisense target sequence; a mir-30 loop sequence; a complement of the anti-sense target sequence; and a lower stem loop complementary to the mir-16 sequence. Methods for down regulating gene expression in a cell using such recombinant nucleic acid molecules are also provided.

Abstract: The present invention relates to an electrochemical method using a permselective membrane for detection of ions in a sample. The permselective electrode includes a lipophilic reagent such as a neutral ionophore or an ion exchanger and a lipophilic ion, the lipophilic reagent being in molar excess relative to the lipophilic ion. The present invention further relates to electrode and electrochemical cell apparatus containing said permselective membrane. The permselective electrode can be used for dynamic electrochemical measurements such as chronopotentiometry.

Abstract: A brain damage-related disorder is diagnosed in a subject by detecting at least one polypeptide, or a variant or mutant thereof, in a sample of body fluid taken from the subject, wherein the polypeptide is one for which the level is either increased or decreased in cerebrospinal fluid from deceased patients compared to cerebrospinal fluid from healthy donors.

Abstract: The present invention relates to compounds of formula (I) wherein R1, R2 and R3 are as defined in the description, to their pharmaceutical compositions and use thereof for the treatment of cancer expressing oncogenic ALK protein, particularly anaplastic large cell lymphoma (ALCL), diffuse large B cell lymphoma (DLBCL), inflammatory myofibroblastic tumors (IMT) and non-small cell lung cancer (NSCLC).

Abstract: The present invention is directed to Nogo-A antagonists useful for the control of blood glucose or blood insulin levels in a subject and related use and formulation thereof. In particular, the invention is directed to Nogo-A antagonists useful for the prevention, repression or treatment insulin secretion deficiency and related methods and pharmaceutical formulations. In particular, the invention relates to Nogo-A antagonists useful in the treatment of diabetes mellitus.

Abstract: The present invention relates to the compounds useful in the prevention and/or treatment of tumors. More specifically the present invention relates to inhibitors of the activity of the electron transport chains and/or the mitochondrial TCA cycle in glioma-initiating cells (GICs) for use in a method for preventing and/or treating tumors presenting glioma-initiating cells (GICs) in a subject who has undergone a prior removal of a tumor glioma bulk. The present invention further provides a pharmaceutical composition containing the inhibitors of the invention and a screening method for identifying the inhibitors of the invention.

Abstract: Endosseous implant to be applied to a human or animal bone, wherein the surface of the implant is made from titanium or a titanium alloy, said implant having a smooth or rough surface texture, which is characterized in that said surface has been treated with at least one selected organic phosphonate compound or a pharmaceutically acceptable salt or ester or an amide thereof; process for producing said implants.

Abstract: The invention relates to a process for providing esters of hyaluronic acid, hyaluronic acid salts or hyaluronic acid derivatives with hydrophobic organic compounds. The process includes the steps of (i) micronizing the hyaluronic acid, salt or derivative thereof at reduced temperature, (ii) reacting the hydrophobic compound with a micronized hyaluronic acid obtained in (i) in a suitable solvent; and (iii) filtrating or dialyzing reaction mixture obtained in (ii) to obtain the desired ester. Also encompassed by the present invention are the esters obtained by such a method and compositions containing them as well as the use thereof for treating and/or preventing cartilage damage and inflammation.